Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.51 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.51 |
| ▸ | FNTA | P49354 | 1/20 | 0.49 |
| ▸ | FNTB | P49356 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.49 |
| ▸ | NAAA | Q02083 | 3/20 | 0.48 |
| ▸ | RRM1 | P23921 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.47 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.46 |
| ▸ | TLR2 | O60603 | 1/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4948525 | 1.00 | SIRT6 (0.51) | SIRT6SIRT1FNTAFNTBEPHX1 | |
| SCHEMBL4949210 | 1.00 | SIRT6 (0.51) | SIRT6SIRT1FNTAFNTBEPHX1 | |
| SCHEMBL9306476 | 0.98 | SIRT6 (0.49) | SIRT6SIRT1FNTAFNTBEPHX1 | |
| SCHEMBL9306465 | 0.98 | SIRT6 (0.49) | SIRT6SIRT1FNTAFNTBEPHX1 | |
| SCHEMBL506608 | 0.87 | SIRT6 (0.67) | SIRT6SIRT1EPHX1NAAARRM1 | |
| SCHEMBL506609 | 0.87 | SIRT6 (0.67) | SIRT6SIRT1EPHX1NAAARRM1 | |
| SCHEMBL25021992 | 0.84 | LPAR3 (0.65) | NAAALPAR3LPAR1TLR2 | |
| SCHEMBL19839845 | 0.84 | SIRT6 (0.63) | SIRT6SIRT1FNTAFNTBEPHX1 | |
| SCHEMBL9306626 | 0.83 | SIRT6 (0.48) | SIRT6SIRT1FNTAFNTBEPHX1 | |
| SCHEMBL9306622 | 0.83 | SIRT6 (0.48) | SIRT6SIRT1FNTAFNTBEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1918287-A2 | LPA receptor agonists and antagonists and methods of use | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2008-05-07 | — | — | EP | disclosed |
| EP-1263752-B1 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2007-12-05 | — | — | EP | disclosed |
| EP-1427424-A4 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2006-12-13 | — | — | EP | disclosed |
| US-20050261252-A1 | LPA receptor agonists and antagonists and methods of use | MILLER DUANE D | 2005-11-24 | — | — | US | disclosed |
| US-6875757-B2 | For therapy of cancer, enhancing cell proliferation, and wound | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2005-04-05 | — | — | US | disclosed |
| EP-1427424-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2004-06-16 | — | — | EP | disclosed |
| EP-1263752-A4 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | UNIV TENNESSEE RES CORP (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030130237-A1 | LPA receptor agonists and antagonists and methods of use | MILLER DUANE D (US) | 2003-07-10 | — | — | US | disclosed |
| WO-2003024402-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2003-03-27 | — | — | WO | disclosed |
| US-20030027800-A1 | LPA receptor agonists and antagonists and methods of use | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-02-06 | — | — | US | disclosed |
| EP-1263752-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001071022-A2 | LPA RECEPTOR AGONISTS AND ANTAGONISTS AND METHODS OF USE | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 2001-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261252-A1 | LPA receptor agonists and antagonists and methods of use | LPAR1, LPAR2, LPAR3 | SIRT6 3616/4885SIRT1 2133/4885FNTA 1405/4885 |
| US-20030027800-A1 | LPA receptor agonists and antagonists and methods of use | LPAR1, LPAR2, LPAR3 | SIRT6 3616/4885SIRT1 2133/4885FNTA 1405/4885 |
| US-20030130237-A1 | LPA receptor agonists and antagonists and methods of use | LPAR1, LPAR2, LPAR5 | SIRT6 3299/4885SIRT1 1855/4885FNTA 1931/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.